U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06806657) titled 'Safety Study in Subjects >= 12 Years of Age With Hereditary Angioedema Switching to Garadacimab' on Feb. 03.
Brief Summary: This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein [KK] inhibitor or plasma-derived C1-esterase inhibitor [pdC1INH]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (>=) 12 years with HAE.
Study Start Date: March 14
Study Type: INTERVENTIONAL
Condition:
Hereditary Angioedema
Intervention:
BIOLOGICAL: Garadacimab
Participants will...